VAFSEO

This brand name is authorized in Austria, Croatia, Estonia, Ireland, Italy, Japan, Lithuania.

Active ingredients

The drug VAFSEO contains one active pharmaceutical ingredient (API):

1	Vadadustat UNII I60W9520VV - VADADUSTAT
	Vadadustat is a hypoxia-inducible factor prolyl-hydroxylase inhibitor which leads to increased cellular levels of hypoxia-inducible factor thereby stimulating endogenous erythropoietin (EPO) production, increasing iron mobilization and red blood cell production, resulting in gradual rate of rise in Hb.
	Read more about Vadadustat

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VAFSEO Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B03XA08		B Blood and blood forming organs → B03 Antianemic preparations → B03X Other antianemic preparations → B03XA Other antianemic preparations
Discover more medicines within B03XA08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3037081, 3037092, 3037104, 3037115, 3037126, 3037137
IT	Agenzia del Farmaco	050660012, 050660024, 050660036, 050660048, 050660051, 050660063
JP	医薬品医療機器総合機構	3999050F1020, 3999050F2026
LT	Valstybinė vaistų kontrolės tarnyba	1097020, 1097021, 1097022, 1097023, 1097024, 1097025